Early Psa Response is an Independent Prognostic Factor in Patients with Mcrpc Treated with Next-Generation Androgen Pathway Inhibitors

Fuerea, Alina; Baciarello, Giulia; Massard, Christophe; Sauvin, L. Albiges; Gizzi, Marco; Terrisse, Safae; Palma, Mario Di; Escudier, Bernard; Fizazi, Karim; Loriot, Yohann

doi:10.1093/annonc/mdu336.44

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One exception is prostate specific antigen (PSA), which is useful for monitoring treatment effects for prostate cancer. In 118 metastatic CRPC patients treated with next generation androgen pathway inhibitors, a PSA response (>50 % decrease in PSA levels from baseline) at 28 days after treatment initiation was associated with longer PFS and OS [64]. In a group of patients treated with the oral androgen receptor antagonist MDV3100, the model most predictive of prolonged PFS consisted of a prolonged decrease in monthly PSA levels at 12 weeks in conjunction with a reduction in CTCs [65].…”

Section: Introductionmentioning

confidence: 99%

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

Amin

Bathe

2016

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe rapidly expanding arsenal of chemotherapeutic agents approved in the past 5 years represents significant progress in the field. However, this poses a challenge for oncologists to choose which drug or combination of drugs is best for any individual. Because only a fraction of patients respond to any drug, efforts have been made to devise strategies to personalize care. The majority of efforts have involved development of predictive biomarkers. While there are notable successes, there are no predictive biomarkers for most drugs. Moreover, predictive biomarkers enrich the cohort of individuals likely to benefit; they do not guarantee benefit.Main textThere is a need to devise alternate strategies to tailor cancer care. One alternative approach is to enhance the current adaptive approach, which involves administration of a drug and cessation of treatment once progression is documented. This currently involves radiographic tests for the most part, which are expensive, inconvenient and imperfect in their ability to categorize patients who are and are not benefiting from treatment. A biomarker approach to categorizing response may have advantages.ConclusionHerein, we discuss the state of the art on treatment response assessment. While the most mature technologies for response assessment involve radiographic tests such as CT and PET, reports are emerging on biomarkers used to monitor therapeutic efficacy. Potentially, response biomarkers represent a less expensive and more convenient means of monitoring therapy, although an ideal response biomarker has not yet been described. A framework for future response biomarker discovery is described.

show abstract

Section: Introductionmentioning

confidence: 99%

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

Amin

Bathe

2016

BMC Cancer

View full text Add to dashboard Cite

show abstract

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

et al. 2015

View full text Add to dashboard Cite

This systematic review assembles current evidence and provides an approach to treatment using available clinical factors. Issues of patient selection, use of laboratory and clinical biomarkers to identify patients at risk of poor outcomes, and the timing and sequencing of available treatment options are addressed. Our findings reveal a lack of high-level evidence regarding predictive factors and treatment of patients with resistance to ARAT therapy, and a need for further research in this area. In the meantime, we suggest practical strategies to guide management of ARAT treatment-resistant patients based on available data.

show abstract

Early Psa Response is an Independent Prognostic Factor in Patients with Mcrpc Treated with Next-Generation Androgen Pathway Inhibitors

Cited by 2 publications

References 0 publications

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

Contact Info

Product

Resources

About